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tR#ctives. This study sought to evaluate the relation, if any, 
between fluid overload in congestive heart failure (CHF) and a 
newly discovered endogenous oatriuretic factor acting like loop 
diuretic drugs: cotraosport inhibitory factor (CIF). 
Eackgm&. The bumoral mechaoisms qpdating volume over- 
load in CHF are not fully understood. merefore, we investigated 
whether there is a role for CIF in this pathologic conditiou. 
Afekds. Plasma and urioary CIF kvels were investigated in 23 
patients with chronic CHF and compared with changes in plasma 
atrial natriuretic peptide (ANP). ‘k&e patients without CHF 
served as control subjects. 
Results. CHF was associated with a highly sign&ant threefold 
increase in both plasma CIF levels (mean f SD 7.10 f 3.01 vs. 
238 f 0.92 U/ml, p c O.iKtOl) and urinaq CIF excretion (7,849 f 
3,600 vs. 2,351 f 1,2!N U/day, p < 0.0001) with respect to patients 
without CIIF. CIF increased as a fun&on of impairment in leIt 
ventricular ejection fkactioo (r = -0.703, p * 0.0001) and the 
severity of clinical status. Plasma ANP was also iorrepsed in 
patients with CHF, Plthough to a lesser exteot (68%. p = 0.0501) 
than plasma CIF, and was also slgnificaatly correlated with left 
ventricular ejection fractioo (r = -0552 p = O.tMtO4). 
Conclusions. Pissma and miuay CIF activities were strongly 
and very signiIkaotly increased in chmuic CHF. In addition to 
Ah’P, this long-term natiuretic agent may he of potential impor- 
tance in reducing fluid overload in CHF. 
(J Am Cdl Chdid 1996;28:1464-70) 
Volume overload, a major disc&r of congestive heart failure 
(CHF), provokes important adjustments in fluid volume regu- 
latory mechanisms. Thus, plasma levels of atrial natriuretic 
peptide (ANP) are elevated in CHF (1,2), and brain natriuretic 
peptide (BNP), which has longer kinetic activity, seems to play 
an important role as a counterregulatory cardiac hormone (3). 
Moreover, other, not fully characterized natriuretic mecha- 
nisms may play a role in CHF. 
We previously described in salt-loaded rats, a new endog- 
enous natriuretic compound acting like loop diuretic drugs, 
that is, potently inhibiting the furosemide-sensitive sodium- 
potassiumchloride (Na-K-Cl) cotransport system (cotransport 
inhibitory factor (CIF) (4-7). Extensive work in the purifica- 
tion and chemical analysis of CIF is being conducted in our 
laboratory ($8). CIF seems to be a steroid compound, chem- 
ically related to the nonpeptide, nondigitalis-like natriuretic 
factor described by Bricker et al. (9) (an isomer of cortisone) 
and different from the previously characterized endogenous 
digitalis-like factors: ouabain or a closely related ko.ner 
(lo,1 1) and bufodienolide (12). 
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In this study, we investigated whether CIF plays a role in 
CHF. Therefore, we measured plasma and urinary CIF in 
patients with CHF. CIF changes were examined in relation to 
changes in ANP and severity of the disease. 
Methods 
Study patients. Twenty-three patients with mild to severe 
symptoms of CHF (14 men, 9 women) aged 55.7 +- 12.6 years 
(Table 1) were studied; 10,7 and 6 subjects were considered to 
be in New York Heart Association functional class II, III or 
IV, respectively. Table 2 shows mean values +SD for the 
reduction in left ventricular ejection fraction and for left 
ventricular dilation in patients in these three functional classes. 
The patients had had symptoms of CHF for >6 months before 
hospital admission. All but five had sinus rhythm. Detected 
etiologic factors are listed in Table 1. Left ventricular ejection 
fraction was determined at the time of the hospital stay by 
contrast or radionuclide angiography. Patients with severe 
renal or hepatic failure were excluded. The usual treatment 
was not modified except for administration of diuretic drugs. It 
is important to note that i) except for loop diuretic drugs, no 
other antihypertensive compound listed in Table 1 can inhibit 
Na-K-Cl cotransport fluxes; 2) 11 patients never re&ived 
diuretic drugs; 3) in 3 patients, diuretic treatment was stopped 
4 days before blood and urine sampling; and 4) in the 
remaining 9 patients, loop diuretics were replaced by thiazide 
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ANWA -1 anabsis of variance 
ANP = atrial natriuretic peptide 
CHF = congestive heart failure 
CIF = mtnnspurt inhihilory factor 
I(;,, = WC; inhibition of CIF actkit\; 
Ptll. = CIF activity in plasma 
U‘ I,: = CIF activity in urine 
Il.-,kV = urinav CIF cxcrrticn 
drugs (compounds that do iior interfere with the CIF assay 
because they are unable to inhrbit cotransport fluxes) 4 days 
before blood and urine sampling. Finally, all patients had a 
controlled low salt diet with 100 mmol daily sodium intake for 
3 days before the study. After withdrawal of blood and urine 
samples, treatment with loop diuretics and the usual sodium 
diet were restored if necessary. 
The study protocol was approved by the Ethics Committee 
of our local hospital, and all patients gave a written informed 
consent. 
Patients without CHF. Twelve patients &hour CHF. 
matched by gender and age with the 23 patients with CHF 
(Table I), were included in the study. These patients had no 
history of cardiac failure, had no symptoms of CHF and had 
normal angiographic left ventricular ejection fraction. Eight of 
the 12 were recruited from a group of patients with angina 
pectoris scheduled for cardiac catheterization. Three had 
medically controlled hypertension. None was receiving diuretic 
therapy. 
Control subjects. Six normal volunteers matched by gender 
and age with the other groups (Table 1) served as a control 
group. These subjects had no history of cardiac disease and had 
normal cardiac function as assessed by echocardiography. 
None was receiving medical therapy. In this group, in contrast 
to the two patient groups, left ventricular ejection fraction was 
not calculated from isotopic or angiographic analysis but 
estimated from echographic analysis. Conseqtiently, we did not 
! I ‘I* 1 host! cjcction fractions for the statistics1 analysis. 
t)lwd and urine sampling. Subjects were confined to bed 
for 8 h until blood samples were withdrawn the following 
morning. Blood samples were obtained by means of an intra- 
venous cannula inserted in an arm vein and flushed with a 
heparinized saline solution. The initial blood samples were 
used for hemoglobin, white cell count and biochemistry deter- 
minations (sodium, potassium, chloride, urea, creatinine). For 
ANP determination, a blood sample of 5 ri*l was collected in a 
tube containing ethylenediaminetetraacetic acid (EDTA) and 
aprotinitr(1 million III/ml). For CIF activity, 10 ml of blood _ 
was collected in a plastic tube. Blood samples for ANP and CIF 
activity determinations were placed in the cold and immedi- ’ 
ately centrifuged at 1,750i for 15 min at 4°C. The supematant 
plasma was removed and stored at -80°C. 
Urine samples were obtained from a 24-h urine collection. 
One sample was processed for the measurement of urea, 
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creatinine, sodium, potassium and chloride. For measurement 
of CIF activity. a second sample was centrifuged at S.ooO~g for 
10 mir, at ?C, and the supematant was removrd and stored at 
- 80°C. 
Measurement of ANP. ANP contents in.plasma were mea- 
sured by using a previously described radioimmunoassay tech- 
nique (13). Briefly, plasma ANP was extracted with Vycor glass 
(Coming Glassware). Absorbed ANP was eluted with water- 
acetone and dried. The pellet was reconstituted in saline 
solution and added to rabbit anti-alpha-atria1 natriuretic 
polypeptide serum and the mixture was incubated at 4°C for 
24 h. The next day, iodine-125ANP (Amersham Labs) was 
added and the mixtures were incubated for an additional 24 h. 
The radiolabel was separated by addition of dextran and 
coated charcoal solution followed by centrifugation. Values 
were expressed in pglml. 
Measurement of CIF activity. For each subject, plasma and 
urine samples were diluted in saline solution and tested in 
concentration-response curves for their inhibitory potency on 
membrane fluxes catalyzed by the Na-K-Cl cotransport system 
(4-7). Na-K-Cl cotransport fluxes were measured in human 
erythrocytes accordingly to a previously described protocol 
(4-7). Brietly, fresh human erythrocytes were loaded with 
lithium (Li) by using the nystatin ionophore (14). Li-loaded 
cells were incubated in Li-free media and Li+ etIlux was 
measured by atomic absorption (14). Na-K-Cl cotransport 
activity was equated :o the bumetanide-sensitae Li+ elIbut (for 
technical details see ref. 4-7,14). 
For each subject, the percent sample dilution. vol/vol. 
required to obtain 50% inhibition of cotransport activity (I&) 
was calculated from the dose-response curves. CIF activity in 
plasma (Pcrr) or urine (Uc,J was calculated as a percent of 
I/&,, and expressed in U/ml. Finally, measurement of daily 
diuresis allowed the calculation of urinary CIF excretion 
(UctrV, see ref. 6,7 for details). 
Statistical methods. All results in figures, tables and text 
are reported as mean value 2 SD. Statistical differences 
between mean values were determined by using an unpaired 
Student t test. Correlations were obtained by linear regression 
analysis. Multiple measurement comparison was performed by 
using an analysis of variance (ANOVA) program followed by a 
Bonferroni/Dunn test. Factorial analysis was also performed by 
using ANOVA. Statistical significance was accepted for p 
values < 0.05. 
Results 
General features. Table 1 shows the general characteristics 
of the subjects studied. The patients with CHF 1) did not differ 
significantly in mare/female ratio and age’ with respect to 
patients without CHF and control subjects, 2) had a strongly 
reduced left ventricu!ar ejection fraction (34.0 + 17.0% vs. 
63.1 ‘2 7.6% in patients without CI-IF, p < O.lXJll). and 3) did 
not differ signilIcantly in general biologic variables, except for 
a small (1.7%) but significant (p = 0.02) decrease in plasma 
sodium levels 
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Table 1. Clinical. Biologic and Therapeu:utic Aspects in thr TW Paticnr Groups and Control Subjects 
Paricnts With CHF Paticnl\ Without CHF Conlnjl Suhjccts 
(n 7 23) 1.n :- I?) (n := !I) 
Mdlc fcmalc IJ’Y 8 ‘4 4’ 
Age or) 55.7 r I?.6 51.2 ‘I I’.3 58.’ f ILlI 
Wcighr (kg) 71.0 7 14,s 7x -: s.s 
Hcighr (cm) I7lJ.S F 7.2 Ii?.!) : 4,3 
Sinu, hillIll IX I' -  h  
L\‘EF 34.0 T 17.u’; ‘+ 6.1.) :I 7.h’; hS .? h’; 
I-1 ioloky 
Conmar) artq dilcaw I? :, 
Valvular disca= -I I 
MI 11 (I 
DCM 3 II 
Hypertension 4 3 
Trestments 
Bcra-hlockcrs 3 i 
Digoxin h II 
Calcium anlagonisls 2 5 
Nitrates 4 4 
ACE inhihilurs I6 3 
Antictragul,ml* N 3 
Aapirin s w 
Diuretic dtug” I! Iv 
Plasma 
Na ::nmol!liter) 136.6 ? !.I)’ 138.Y f I.9 
K (mmol:litcr) 3.x * II.4 4.1 2 0.3 
L’rl:a (mmc~l!lircr! n.3 -c 3.1 6.5 2 0.s 
Crratininc (pmollitsr) III.1 -c 28.7 IM.8 c 21.x 
I!rinc 
Volume (ml/24 h) I.163 t 331 1.315 + 358 
Na (mmolili~cr) 56.0 ? 22.2 67.5 2 33.x 
K (mmol;lilcr) 49.4 i 24.6 43.3 -c 22.8 
Urea (mmol:‘litc<) 224 5 83 23x _c 12.5 
Creatinine (~molilitcr) 7x5 ? 5.5 111.4 _c 3.5 
hndtocri1 39.3 t 5.4% 42.4 ! s.v; 
*,tp < 0.05 (by unpaired Srudenl I test) for paticnls with congcslivc heart failure (CHF) versus ‘patients wirhouf 
CIIF or tcontrol suhjcctr. Values presuntcd arc mean value 2: SD. ACE = angiotrnsinconverting enzyme; DCM = 
dilated cardiomyopalhy; K = potassium; MI = myocardial infarcriun: Na = sodium. 
Atrial natriuretic peptide. Table 3 shows plasma ANP (p = 0.0501) with respect to patients without CHF. Finally, 
concentration values in the three groups. Mean plasma ANP hypertension and cardiac rhythm were without significant 
levels were increased in patients with CHF (by 68% and 150% influence on ANP levels (ANOVA factorial analysis; most 
with respect to patients without CHF and control subjects, patients were normotensive and had sinus rhythm). 
respectively). These increased ANP levels in patients with Mean plasma ANP was 49% higher in patients without 
CHF were 1) statistically significant with respect to values in CHF than in control subjects, although the difference was not 
control subjects, and 2) at the limit of the statistical significance statistically significant (even the nine normotensive patients 
Table 2. Angiographic and Echographic Data in the Two Patient Graups 
Patients With CHF 
Palients Without NYHA Class II NYHA Class HI NYHA Class IV 
CHF (n = 12) (n = IO) (n = 7) (n = 6) 
LVEF (%) 63.1’7.6 q.0 c 15.(1* *24.1 r t3.u.t 22.2 2 wt 
LVEDD (mm) 51.4 t 3.0 55.5 % 9.N 61.0 t 7.1’ 64.1 -t 8.4’ 
‘p < 0.05 comparing patients with and without congestive heart failure (CHF). tp < 0.05 comparing patients with CHF in New York.Heart Association (NYHA) 
functional cl= II with patients with CHF in functional classes III and IV. Values presented are mean value 2 SD. LVEDD = left ventricular end-diastolic diameter. 
LVEF = left ventricular ejection fraction. 
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Tabk 3. Atrial Natriuretic Peptide and Cotranspurt Inhibitory Factor Levels in the Two Patient 
Groups and Control Subjects 
Patients With CHF P&r& Without CHF Control Suhjeck 
(n = 2.3) (Il = 12) (n = 6) 
ANP (p@rnl) 123.6 z 7@.7t 73.3 ?r 67.0 49.3 % XG 
Plasma CIF (UrnI) 7.10 + .m*t ?.2l ? 0.93 1.X rr 0.3Y 
Urinary CIF cxcmtion (U!day) ‘*MY ‘c 3.6uo’ 2.m + 1.297 
‘p < O.ti comparing paliems with and without congestive heart failure (CHF). tp i 0.05 rnmparing patients and 
cumrol sub+&. Values presented are mean value t SD. GNP = atrial natriurelic peptide; CIF = ctitranqxxf inhrhitory 
without CHF had 69.4% higher ANP levels than those of 
control subjects). 
CIF. For each subject, plasma and urine samples were 
diluted at different concentrations and tested for their inhibi- 
tory activity on cotransport fluxes as described in the Methods 
section. Figure 1 shows concentration-response cmves for 
cotransport inhibitory potency (mean values + SD) of plasma 
(upper panel) and urine (Iower PpIwo. Only the two patient 
groups (with and without CHF) are represented in this figure. 
At each diluticri;, p!?qma and urine from patients with CHF 
induced a highly significant (p i StMt: ANOVA multiple 
m 1. Inhibition of sodium-potassium-chloride (Na-K-Cl) cotrans- 
port fluxes hy plasma (upper pllwl) and urine (kr pucl) from 
patients with chronkxtingestivc ileart failure (CHF). Values presented 
are mean value -t SD. Statistical significance was calculated by using 
analysisof variance nlultiple measurement comparison followed by the 
Bonferrdlhm tes’. v = volume. 
I 
i io I 






1% IJrllK colmmlltloll [v/v]) 
measurement comparison followed by BonferroniiDunn test) 
and more potent cotransport inhibition than did plasma or 
urine from patients without CHF. 
For each subject. the plasma or urine dilution required to 
achieve IC, was calculated from kdividual curves similar to 
that of Figure 1 (see Methods). Plasma from patients with 
CHF had 2.9 times lower 1C& for cotransport inhibition than 
that of patients without CHF (IC, 17.0 2 9.2% vs. 49.2 2 
16.1%. p < 0.0001). This decrease in I& was still greater (4.6 
times) when patients with CHF were compared with the 
healthy control subjects (IC, 77.7 2 19.2%). Moreover, it was 
indcpesdent of diuretic treatment; that is, patients untreated 
with diuretic drugs had an 12~ \ ‘X.! 2 3.5%. n - 11) similar 
to that of patients whose treatment with loop +reiiti ;vd 
Interrupted before the sludy (Ml + 1.7%, n = 12). It is 
important to mention that 1) interassay and intraassay varia- 
tions in IC, values were 13.4% and 4.3%. respectively 
(SD/mean in %, n = 6): and 2) in the healthy control subjects, 
IC,, was mokstly (5??S) bc! +ifc~~!!y (p = !!.!XY?! higbcr 
than in the patients without CHF. 
Similar results were obtained with urine samples. Thus, 
patients with CHF had a 3.7 times lower IC, for cotransport 
inhibition than did petientswithout CHF (I& 175 + 8.3% vs. 
65.1 2 22.9%. respectively, p < O.OOOl), and this lower I& 
was also independent of diuretic treatmen!. 
For each subject, plasma CIF activity (P& and urinary 
CIF excretion (UCIFV) were calculated from the individual 
values of ICs(, and daily diuresis as described in the Methods 
section. Table 3 shows that patients with CHF had a highly 
significant (p < O.MHll) threefold increase in both PCIF and 
UcrFV with respect to values in patients without CHF. The 
increase in PCiF was still higher (5.2 times) when patients with 
CHF were compared with healthy control subjects (Table 3, 
p c 0.0001). Hypertension and cardiac rhythm were without 
significant influence on both PcIF and UopV (most patients 
were normotensive and had sinus rhythm). 
To investigate the influence of CHF etiology, patients with 
CHF who had coronary artery disease, normal blood pressure 
and sinus rhythm were compared with patients with CHF 
without coronary d&a&. Table 4 shows no significant di!fer- 
ences between these two subgroups in plasma ANP or CIF 
levels or urinary CIF excretion. 
Patients without CHF showed a modest but significant 
increase in PCIF (68%, p = 0.033) with respect to values in 
control subjects (Table 3). and even the nine nonnotensive 
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patirnts without CHF had P,,,r; levels significantly highrr 
(77Xi. p = 0.017) than those of control subjects. 
I’ (‘II and U,.,,.V values wcrc strongly correlated (r = 0.79. 
p ( lWl~~1) in th.: total study group. This correlation remained 
statistically significant (r = 0.597? p - O.l!!!??) in !hc group of 
patients with CHF alone. PcIIF values iverc z!:;:: sigr,ificar~ly 
correlated with plasma ANP values (r = 0.376. p = 0.0148) in 
tht= torn1 study group. However. the correlation was not 
statistically significant in patients with CHF alone (r = 0.295, 
p = O.OXS9). 
ANP and CIF levels as a function of severity of disease. 
The inclusion of patients without CHF. whose left ventricular 
cjcction fraction was measured angiographically. allowed us to 
investigate the influence of this variable. Figure 2 shows that 
both plasma CIF and plasma ANP were significantly correlated 
with ejection fraction (for CIF. r = -0.703, p < O.OlMl; for 
ANP. r = -0.552, p = O.ftOO4). 
Urinary CIF excretion was also strongly correlated (r = 
-0.h75. p < O.OOOI) with left ventricular ejection fraction. All 
correlations pcrsistcd when only patients with CHF were 
t:onsidcred: plasma CIF, r = -0.492, p = 0.019 and urinary CIF 
excretion. r = -0.428. p = 0.046. Figure 3 shows that plasma 
CIF levels tended to be significantly higher in patients with 
poor clinical status (p < 0.05 for functional class IV vs. class II). 
Discussion 
Volume overload in CHF is a consequence of the inability 
of the kidney to cxcrcte sodium (due to the high leI;els of 
neurohormones and a decreased renal blood flow). The ho- 
meostatic mechanisms regulating sodium excretion by the 
kidney in normal and pathologic conditions have been inves- 
tigated for many years. These studies revealed that glomerular 
filtration rate, renin-angiotensin-aldosterone system, renal 
nerves and ANP are major regulators of renal sodium excre- 
tion. However, there is evidence that other poorly understood 
mechanisms should play an important role. Thus, several 
authors suggested the existence of circulating natriuretic fac- 
[R = -0.703; p < O.OWl 
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Figure 2. Plasma cotransport inhibitory factor (CIF) (upper panel) 
?nd atrial natriurctic pcptide (ANP) (lower panel) as a function of left 
ventricular cjcction fraction (LVEF). The impairment in cjcction 
fraction was strongly corrclatcd with the incrcasc in both natriurctic 
factors. Symbols arc the same for hoth panels. NYHA I, 2, 3,4 = New 
Yark Heart Association functional classe% I, II, III and IV, respec- 
tively. 
tors inhibiting the sodium-potassium pump (or sodium- 
potassium-adenosine triphosphatase) in the renal tubule (for 
review see ref. 15). One of these endogenous digitalis-like 
compounds was reported to possess a chemical structure 
similar to that of ouabain (10.1 I), whereas a second one seems 
to be a bufodienolide (12). However. oral or intravenous 
cardiac glycosides are unable to product natriuresis, and the 
interest in endrgenous digitalis-like substances has switched 
from a role in voll;me regulation to a role in blood pressure 
regulation. 
CIF is a newly identified neurohumoral natriuretic com- 
pound that is different from the endogenous “digitalis-like” 
substance (it does not inhibit the sodium-potassium pump or 
sodium-potassium:adenosine triphosphatase, ref. 4-7). This 
compound, which is undergoing extensive characterization in 
our laboratory: inhibits the furosemide-sensitive Na-K-CI co- 
transport system, a transport system catalyzing sodium chlo- 
ride reabsorption at the lumen side of the thick ascending limb 
of Henle’s loop. 
Preliminary evidence suggesting the existence of CIF came 
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Figurn 3. Plasma cotransport inhihhq factor (CIF) levels in patients 
with congestive heart hilurc as a function of severity of clinical status. 
Values presented are mean value 2 SD. I*** and * indicate p -Z 
MllHll and p c 0.05. respcctivaly. NYHA I. 2,3.4 = New York Heart 
Association functional clasws I, II. III and IV. respectively. 
from observations in healthy human subjects that oral (16) or 
intravenous (I 7j salt loading provokes the inhibition of co- 
!r~ncport fluxes in erythrocytes. Recently. CIF directly de- 
tected in urine from salt-loaded rats was found to poiruiiy 
inhibit cotransport fluxes in Madin and Darby canine kidney 
line (MDCK) cells and human erythrocytes (4). A partially 
purified urinary fraction enriched in CIF was therefore pre- 
pared and intravenously infused in rats (5). This procedure 
potently increased renal sodium and water excretion for long 
periods, leaving total urinary potassium unchanged. Recently. 
we (7) reported that salt-loading in rats induced the appear- 
ance of CIF activity in the neurohypophysis. In addition to the 
different sites of secretion and mechanisms of action of CIF 
and ANP. one intriguing question is the need for two natri- 
uretic factors. Experiments in rats (6.7) revealed that CIF and 
ANP have very different although complementary kinetic 
behaviors. Thus, long-term salt-loading in rats induced 1) a 
rapid and transient increase in plasma ANP levels (with a peak 
within the 1st 24 h), and 2) a delayed urinary CIF excretion, 
that increased slowly. reaching stationary levels after 4 to 6 
days of salt loading (6.7). Taken together, these results show 
that I) CIF is a newly identified neurohumoral natriuretic 
factor with a part but not all of the biologic profile of loop 
diuretic drugs. and 2) in contrast to ANP, CIF seems to 
regulate long-fear renal sodium excretion. 
Several observations and assumptions suggested to US that 
CIF could be increased and play an important compensatory 
role in CHF. First, ANP (1,2) and endogenous ouabain (18) 
are increased in CHF. and CIF tends often to change in 
parallel with these two factors. Second, we considered it likely 
that a long-term rstriuretic factor would regulate chronic 
volume overload. Finally, CIF has a profile similar to that of 
loop diuretic drugs, which are useful in treating volume 
overload in CHF. 
The present study revealed important increases in plasma 
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and urinary CIE activity in patients with CHF. ANP or the 
“digitalis-like” compound cannot account for such results, 
because 1) neither compound is able to inhibit Ma-K-Cl 
cotransport in human red cells (IY). and 2) purified, CIF 
preparations were free froin immunoreactivr ANP and digoxin 
activity (5). Moreover, an interference of diuretic treatment 
was excluded because only loop diuretics can inhibit erythro- 
cyte cotransport. CIF was increased to a similar e.xtent in 
patients who never received diuretic drugs and the increase in 
CIF was independent of previous diuretic treatment. 
Increaser in plasma CIF were twice as great as those of 
plasma ANP and were very significantly correlated with the 
decrease in left ventricular ejection fraction (r = -0.703. p < 
O.otXll). Urinary CIF excretion was also increased in patients 
with CHF and was also highly significantly correlated with the 
decrease in ejection fraction. 
To investigate the influence of left ventricular ejection 
fraction, we also studied patients without CHF. This group, 
which included patients with hypertension and coronary artery 
disease, showed a modest (68%) but significant (p = 0.033) 
increase in P<.,r: with respect to values in healthy control 
subjects. Therefore. 1) patients with CHF had still higher and 
even more significant increases in plasma CIF activity with 
respect to values in healthy control subjects than with respect 
to va!ues in pa!Ien!s withnut CHF (Table 3). and 2) other 
cardiovascular abnormalities should also increase CIF. al- 
though to a much lower extent than the increase induced by 
CHF. 
Our results suggest that CIF can be a new biochemical 
marker of CHF. As such. CIF has the advantage of remaining 
stahle in cold temperatures. The assay of cotransport fluxes is 
very sensitive and precise but not easily adapted to large scale 
CIF quantification. Therefore, an effort should be made to 
develop radioimmunoassays allowing large scale CIF measure- 
ments, This step requires further clinical studies and further 
chemical characterization of CIF. 
Limitations of the study. The main limitation of this study 
is that cotransport inhibition in patients with CHF was studied 
with use of a biologic assay without providing chemical char- 
acterization of CIF. Indeed, such chemical work was initiated 
in our laboratory as soon as bioassays revealed the presence of 
large amounts of CIF in urine from salt-loaded rats (4). That 
investigation revealed that rat urine has at least two com- 
pounds with CIF activity: 1) equol (3.4-dihydro-3-(4- 
hydroxyphenyl)-2H-I-benzopyran-7-ol), an ‘estrogen-like” 
isoflavonoid that is synthesized by intestinal bacteria and 
explains basal urinary CIF activity, and 2) a retropituitary CIF 
compound that is evoked by salt loading (8). This latter 
compound, a very potent cotransport inhibitor was present in 
lovver concentrations. than equol; we hope to report on its 
structure in the near future. Human urine contains much lower 
amounts of equal (co.1 pmoliliter) than does rat urine (-20 
pmol/liter [S]). Therefore, it seems unlikely that equal inter- 
fered with the measurement of ClF activity in our patients with 
CHF. 
Similarly. the demonstration of cotransport inhibition 
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should be done at the Henle’s loop level. Finally. nothing is 
knoyn concerr$ng !he regulatory mechanisms of CIF secretion 
by the neurohypophysis. Despite such limitations, this study is 
the first lo drmonsrrate the presence of an endogenous 
natriuretic’ factor other than ANP in CHF. ‘ihere it can have 
an important regulatory role. 
Another limitation was the small size of the study group and 
the heterogeneity of patients with CHF. However, within the 
homogeneous group of patients with ischemic cardiomyopa- 
thies. CIF values were not different from those found for the 
total study group. Moreover. few patients were hypertensive or 
without sinus rhythm, and these factors did not significantly 
influence CIF levels. Therefore, CHF seems to be a main 
factor increasing CIF levels, independent of etiology and other 
potentially confounding factors. 
Clinical implications. The present study suggests that in 
addition 10 changce in ANP. changes in CIF in patients with 
CHF can express the triggering of homcostatic. long-tram 
mechanisms to counterbalance the sodium and water retention 
that characterizes this disease. The presence of an endogenous 
compound that acts like furosemide suggests that different 
levels of natriuresis could be regulated by CIF and that the 
pathologic consequences of fluid retention may be due to 
abnormal CIF regulation. This hypothesis merits ccmfirmation 
by further studies. Such studies can open up an attractive new 
field of research that may improve our understanding of CHF, 
although whether CIF research will lead to different therapeu- 
tic approaches to CHF is speculative. 
In conclusion, plasma and urinary CIF activity was strongly 
and very significantly increased in patients with CHF. Increases 
in CIF were very significantly correlated with the decrease in 
left ventricular ejection fraction. These changes in CIF are of 
potential importance as they can express the triggering of 
homeostatic. long-term mechanisms to counterbalance fluid 
overload in CHF. Other studies are required to further char- 
acterize the chemical structure of CIF and its role in CHF. 
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